---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-001063"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:34:37.961731+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Positive Phase 1b asthma data for zumilokibart; FeNO reduction 60%, durable to 32 weeks; 2026 milestones

## Summary
- Zumilokibart showed maximum mean FeNO reduction of 45 ppb (60% decrease) after single 720 mg dose; suppression durable through 16 weeks in all patients and up to 32 weeks in some.
- Favorable safety profile: no Grade ≥3 TEAEs, SAEs, conjunctivitis, injection site reactions, or anti-drug antibodies; TEAEs included GERD and upper respiratory infection.
- Positive trends in FEV1 and Type 2 biomarkers; further data to be presented at medical conferences.
- 2026 milestones: APEX Part A (AD, 52-week) data Q1; Part B (16-week) data Q2 (347 patients enrolled); Phase 3 AD start 2H 2026; APG279 vs DUPIXENT readout 2H 2026 (80 patients).
- Pro forma cash $913M as of Sept 30, 2025; cash runway into 2H 2028 supports advancement to potential 2029 launch.

## SEC filing metadata
- accession: 0001104659-26-001063
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465926001063/0001104659-26-001063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465926001063/tm261950d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-001063
- JSON: https://secwatch.observer/filing/0001104659-26-001063.json
- Plain text: https://secwatch.observer/filing/0001104659-26-001063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.